We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Empiric Therapy with BRAF and MEK Inhibitors in Metastatic Melanoma.
- Authors
Cann, Christopher G.; Tillman, Benjamin F.; Davis, Elizabeth J.; Johnson, Douglas B.
- Abstract
BRAF and MEK inhibitors are highly active in the setting of BRAFV600 mutant melanoma. Rarely, patients without previous testing present with fulminant progression necessitating emergent treatment prior to BRAF testing results. The safety and efficacy of empiric treatment in this setting is unclear. Herein, we present two patients treated with empiric BRAF and MEK inhibitors, resulting in dramatic clinical improvement in one patient later found to have a BRAF mutation, and lack of improvement (but no accelerated progression) in a patient lacking this mutation. Empiric BRAF and MEK inhibitor treatment should not be routinely pursued but may be given safely in rare, emergent situations. This brief communication presents case reports for two patients with metastatic melanoma treated empirically with BRAF and MEK inhibitors.
- Subjects
ANTINEOPLASTIC agents; PROTEIN kinase inhibitors; MELANOMA; METASTASIS; GENETIC mutation; ONCOGENES; PATIENT safety; THERAPEUTICS
- Publication
Oncologist, 2019, Vol 24, Issue 11, p1495
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1634/theoncologist.2019-0332